...
首页> 外文期刊>Polski Przegland Chirurgiczny >The Evaluation of Diagnostic Value of the Tumor Markers: CCSA-2 and CEA in Colorectal Cancer
【24h】

The Evaluation of Diagnostic Value of the Tumor Markers: CCSA-2 and CEA in Colorectal Cancer

机译:肿瘤标志物CCSA-2和CEA在大肠癌中的诊断价值

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The Evaluation of Diagnostic Value of the Tumor Markers: CCSA-2 and CEA in Colorectal CancerFinding the biomarker or biomarkers with high sensitivity and specificity in colorectal cancer, and thus a high diagnostic value will determine their clinical usefulness in clinical practice. An effective noninvasive blood test would be an ideal method to detect colorectal cancer. Discovered in 2007 a novel tumor marker CCSA-2 showes a promising results in patients with colorectal cancer.The aim of the study was the evaluation of diagnostic and clinical value of a novel marker - colon cancer specific antigen-2 (CCSA-2) in colorectal adenocarcinoma in comparison to carcinoembryonic antigen (CEA) in patients operated during the years 2008 to 2010 at Wroc?aw Medical University 1st Department and Clinic of General, Gastroenterological and Endocrinologic Surgery.Material and methods. The study was performed on 40 patients with colorectal cancer and 40 patients in control group consisted of healthy subjects who had colonoscopy examinations with negative results (no pathology in the colon was found). The obtained results were statistically analyzed using nonparametric tests - Mann Whitney U and Kruskal-Wallis and Spearman's rank correlation coefficients. To determine the clinical value of CCSA-2 and CEA in those groups, their sensitivity and specifity was evaluated using ROC analysis. This analysis determines the accuracy and diagnostic value of both tests.Results. There was a positive correlation between markers in patients with colorectal cancer and a statistically significant relationship according to which respondents with higher concentrations of CCSA-2 also have higher concentrations of CEA (R=0.754, p<0,001). Concentrations of tumor markers increase and correlate with the clinical progression of the disease. Accuracy of CCSA-2 test using ROC analysis showed a slightly lower measurement of antigen CCSA-2 as diagnostic value in colorectal cancer in comparison to measurement of antigen CEA (accuracy of tests: CCSA-2 - 52%, CEA - 60%).Conclusions. CCSA-2 as a single tumor marker has a low diagnostic value in colorectal cancer because of low sensitivity and specifity. The diagnostic value of novel marker is slightly lower than previously understood and accepted in clinical practice - CEA.
机译:肿瘤标志物CCSA-2和CEA在大肠癌中的诊断价值评估寻找对结肠直肠癌具有高敏感性和特异性的生物标志物,因此高诊断价值将决定其在临床上的临床实用性。有效的无创血液检查将是检测大肠癌的理想方法。 2007年发现的一种新的肿瘤标志物CCSA-2在结直肠癌患者中表现出了令人鼓舞的结果。大肠腺癌与癌胚抗原(CEA)的比较,在2008年至2010年期间在弗罗茨瓦夫医科大学第一科和消化内科及普通外科门诊进行手术的患者。材料和方法。该研究针对40名结直肠癌患者和对照组中的40例健康受试者进行了结肠镜检查,结果均为阴性(未发现结肠病理)。使用非参数检验-Mann Whitney U和Kruskal-Wallis以及Spearman的秩相关系数对获得的结果进行统计分析。为了确定CCSA-2和CEA在这些组中的临床价值,使用ROC分析评估了它们的敏感性和特异性。该分析确定两个测试的准确性和诊断价值。大肠癌患者的标志物之间存在正相关,并且具有统计学上的显着相关关系,根据该关系,CCSA-2浓度较高的受访者也具有较高的CEA浓度(R = 0.754,p <0.001)。肿瘤标志物的浓度增加并且与疾病的临床进展相关。使用ROC分析进行的CCSA-2测试的准确性显示,与抗原CEA的测量值相比,抗原CCSA-2的测量值在结直肠癌中的诊断价值略低(测试的准确性:CCSA-2-52%,CEA-60% )结论。由于敏感性和特异性低,CCSA-2作为单一肿瘤标志物在大肠癌中的诊断价值较低。新型标记物的诊断价值略低于先前在临床实践中公认的CEA值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号